Engineered proteins from transgenic animals

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 2R44GM090626-02A1
Agency Tracking Number: R44GM090626
Amount: $1,805,815.00
Phase: Phase II
Program: SBIR
Awards Year: 2012
Solitcitation Year: 2012
Solitcitation Topic Code: NIGMS
Solitcitation Number: PA11-096
Small Business Information
CRYSTAL BIOSCIENCE, INC.
5980 Horton Street Suite 405, EMERYVILLE, CA, 94618
Duns: 827377933
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 PHILIP LEIGHTON
 (510) 768-7758
 pal@crystalbioscience.com
Business Contact
 PHILIP LEIGHTON
Phone: (510) 768-7758
Email: pal@crystalbioscience.com
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): Approximately 25% of the products being developed by the biotechnology industry are antibodies and many of these antibodies are directed to epitopes on human cells and tissues. We are proposing a novel concept for the production of antibodies with therapeutic potential that is based on recent advances in protein-protein interactions and recent developments in transgenic technology. Execution of this concept will obviate many of the expensive and time consuming modifications that are frequently required after potentially therapeutic monoclonal antibodies are identified in order to optimize their pharmacological properties and to make them amenable to large scale production. By combining recent data derived from in vitro studies with the nascent understanding of genomics, we will extend the range of epitopes that can be accessed and, therefore, extend the range of potentially therapeutic antibodies. PUBLIC HEALTH RELEVANCE: During the past 15 years, more than 20 therapeutic antibodies have been developed to treat human disease, particularly in the fields of autoimmunity and cancer. We have proposed a novel method to obtain potentially therapeutic antibodies that will recognize targets that cannot be obtained from conventional sources. In addition, the technology will engineer antibodies that have improved pharmacological attributes and better manufacturing properties. This technology will provide a cost-effective route to increasing the range of therapeutic candidatesfor the treatment of human disease.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government